4//SEC Filing
Ratliff John D 4
Accession 0001127602-18-005415
CIK 0000920148other
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 2:08 PM ET
Size
10.1 KB
Accession
0001127602-18-005415
Insider Transaction Report
Form 4
Ratliff John D
CEO, Covance Drug Development
Transactions
- Exercise/Conversion
Common Stock
2018-02-09+6,100→ 11,530 total - Tax Payment
Common Stock
2018-02-09$168.08/sh−2,132$358,347→ 9,398 total - Exercise/Conversion
Restricted Stock Unit
2018-02-09−6,100→ 9,827 total→ Common Stock (6,100 underlying)
Holdings
- 80(indirect: By Trust)
Common Stock
- 40(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- [F2]Stock withholding to satisfy tax withholding obligations.
- [F3]The reporting person is not a trustee of the irrevocable trust and disclaims beneficial ownership of the shares.
- [F4]The Restricted Stock Units vest in three equal annual installments beginning on 2/9/2017.
- [F5]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
Documents
Issuer
LABORATORY CORP OF AMERICA HOLDINGS
CIK 0000920148
Entity typeother
Related Parties
1- filerCIK 0001575951
Filing Metadata
- Form type
- 4
- Filed
- Feb 12, 7:00 PM ET
- Accepted
- Feb 13, 2:08 PM ET
- Size
- 10.1 KB